4D Molecular Therapeutics (FDMT) said Friday that it will focus on two product candidates: 4D-150 for wet AMD and DME, and 4D-710 for cystic fibrosis.
The company said the two candidates have the strongest clinical proof of concept within its product pipeline.
4D said it is on track to begin late-stage trials for wet AMD in Q1 and Q3 respectively, with primary endpoint 52-week topline data expected in H2 2027.
Shares of the biotech firm were up 5.7% in recent premarket activity.
Price: 6.16, Change: +0.32, Percent Change: +5.65
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。